<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03886155</url>
  </required_header>
  <id_info>
    <org_study_id>18-1511</org_study_id>
    <nct_id>NCT03886155</nct_id>
  </id_info>
  <brief_title>Cardiac Amyloidosis Screening at Trigger Finger Release</brief_title>
  <acronym>CAST</acronym>
  <official_title>Cardiac Amyloidosis Screening at Trigger Finger Release</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will prospectively evaluate for the presence of amyloid deposits in soft
      tissue samples obtained from patients undergoing trigger finger release surgery. Patients who
      have tissue that stains positive for amyloid will be referred to an amyloidosis specialist.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective study in 2001 showed that 23% (n = 47) of biopsies for idiopathic trigger
      finger were positive for Congo red staining but negative for ATTR and AL amyloid via
      immunohistochemistry. However, mass spectrometry is now the preferred method to type amyloid
      tissue. Trigger finger pathology involves the same flexor tenosynovium that passes through
      the carpal tunnel and has been biopsied to diagnose amyloidosis. Our recent study found that
      10% of older patients undergoing carpal tunnel release surgery were positive for amyloidosis,
      with 20% of that group presenting with cardiac involvement. 60% of the amyloid-positive group
      had a history of trigger finger. Surgical intervention for trigger finger could provide an
      opportunity to screen for amyloidosis through tenosynovial biopsy.

      This study will look at the prevalence of amyloidosis in patients undergoing surgical
      intervention for idiopathic trigger finger. The study hypothesis is at least 10% of such
      patients will be positive for amyloidosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of amyloidosis in older patients undergoing trigger finger release</measure>
    <time_frame>Baseline to 30 days</time_frame>
    <description>Incidence of amyloid deposits in soft tissue removed from trigger finger tenosynovium in older patients undergoing trigger finger release surgery</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Amyloidosis</condition>
  <condition>Trigger Finger</condition>
  <condition>Transthyretin Amyloidosis</condition>
  <condition>Primary Amyloidosis of Light Chain Type</condition>
  <arm_group>
    <arm_group_label>Trigger Finger Biopsy</arm_group_label>
    <description>Biopsy of trigger finger tenosynovial tissue during trigger finger release surgery sent to pathology for amyloid-specific analysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy</intervention_name>
    <description>During clinically-scheduled trigger finger release surgery, soft tissue will be removed from the trigger finger tenosynovium (which may include synovial sheath and subcutaneous fat tissue) and send to pathology to be analyzed with amyloid-specific staining.</description>
    <arm_group_label>Trigger Finger Biopsy</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Trigger finger tenosynovium (may contain tenosynovial tissue and subcutaneous fat)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing trigger finger release surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥50 years at the time of surgical biopsy.

          -  Undergoing surgical intervention for idiopathic trigger finger.

          -  Able to consent.

        Exclusion Criteria:

          -  Known history of amyloidosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mazen A Hanna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mazen A Hanna, MD</last_name>
    <phone>2164443490</phone>
    <email>Hannam@ccf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joseph P Donnelly, MD</last_name>
    <phone>3028932315</phone>
    <email>donnelj@ccf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanna Mazen, M. D.</last_name>
      <phone>216-444-3490</phone>
      <email>hannam@ccf.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cordiner-Lawrie S, Diaz J, Burge P, Athanasou NA. Localized amyloid deposition in trigger finger. J Hand Surg Br. 2001 Aug;26(4):380-3.</citation>
    <PMID>11469845</PMID>
  </reference>
  <reference>
    <citation>Sperry BW, Reyes BA, Ikram A, Donnelly JP, Phelan D, Jaber WA, Shapiro D, Evans PJ, Maschke S, Kilpatrick SE, Tan CD, Rodriguez ER, Monteiro C, Tang WHW, Kelly JW, Seitz WH Jr, Hanna M. Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release. J Am Coll Cardiol. 2018 Oct 23;72(17):2040-2050. doi: 10.1016/j.jacc.2018.07.092.</citation>
    <PMID>30336828</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 20, 2019</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2019</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Mazen Hanna MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Surgery</keyword>
  <keyword>Surgical release</keyword>
  <keyword>Biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin Light-chain Amyloidosis</mesh_term>
    <mesh_term>Trigger Finger Disorder</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

